[Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
OBJECTIVE
To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.


METHODS
The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed. Statistical analyses were performed with SSPS 10.0 software.


RESULTS
The most frequently site of the lesions in the 32 patients was the large intestine (n = 16, 50.0%), followed by small intestine (n = 8, 25.0%), ileocaecal region (n = 6, 18.8%) and multiple intestinal sites (n = 2, 6.2%). Clinical presentations were as follows: abdominal pain and/or distention (n = 26, 81.2%); abdominal mass (n = 14, 43.8%); diarrhea (n = 12, 37.5%); melena (n = 10, 31.3%); weight loss (n = 10, 31.3%) and fever (n = 8, 25.0%). Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma. Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma. Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response. Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).


CONCLUSIONS
The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically. Most of the histological types are diffuse large B-cell type lymphoma. Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease. The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
Bai
Chun-mei
CM
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. baichunmei1964@yahoo.com.cn
Yang
Ti
T
Xü
Ying
Y
Zhang
Wei
W
Liu
Xiao-li
XL
Zhu
Yan-lin
YL
Chen
Shu-chang
SC
Shen
Ti
T
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone